Please login to the form below

Not currently logged in
Email:
Password:

axi-cel

This page shows the latest axi-cel news and features for those working in and with pharma, biotech and healthcare.

New trial results suggest CAR-T effects are durable in lymphoma

New trial results suggest CAR-T effects are durable in lymphoma

Yescarta (axicabtagene ciloleucel or axi-cel) which was approved for that indication the previous October and made $40m in the first quarter, ahead of the $16m predicted by analysts. ... Celgene and Juno are hoping to crash the party soon with their

Latest news

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    At a stroke, Gilead becomes a front-runner in the race to bring the first CAR-T to market with Novartis, claiming Kite's late-stage candidate axicabtagene ciloleucel (axi-cel ... Kite also has a pipeline of other CAR-T therapies following behind axi-cel,

  • Kite starts EU trial of lead CAR-T therapy Kite starts EU trial of lead CAR-T therapy

    Kite Pharma has treated its first European patient with axicabtagene ciloleucel (KTE-C19 or axi-cel), its CAR-T therapy for B-cell lymphomas. ... The start of the trial comes after Kite has already filed for approval of axi-cel in the EU based on the

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Headline. $m. Kite (US). Gilead (US). Company acquisition. CAR-T technology with lead product ‘axi-cel’ under priority review at the FDA for treatment of refractory aggressive NHL.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics